[Form 4] NewAmsterdam Pharma Company N.V. Warrant Insider Trading Activity

Rhea-AI Filing Summary

Insider sale by NewAmsterdam Pharma Company N.V. officer and director. The reporting person, Louise Frederika Kooij, identified as the company's Chief Accounting Officer and a director, reported a sale of 8,269 ordinary shares on 08/25/2025 at a weighted average price of $24.86 per share. After the reported sale, the filing shows the reporting person beneficially owned 15,000 ordinary shares (direct ownership). The form notes the reported price is a weighted average from multiple transactions priced between $24.74 and $24.92, and that the filer can provide the exact share counts per trade on request.

Positive

• None.

Negative

• Insider sale of 8,269 ordinary shares on 08/25/2025, reducing holdings to 15,000 shares (direct ownership)

Insights

Financial Analyst

TL;DR: Insider sale of 8,269 shares at ~$24.86; transaction appears routine given disclosure.

The filing documents a straightforward open-market sale by a senior officer who is also a director. Key facts: sale date 08/25/2025, 8,269 shares sold at a weighted average price of $24.86, price range $24.74–$24.92, and remaining beneficial ownership of 15,000 shares. Without additional context on holding period, company size, or trading volume, this sale alone provides limited signal on fundamentals but is material as a change in insider holdings.

Corporate Governance Expert

TL;DR: Disclosure satisfies Section 16 reporting; no governance red flags in the form itself.

The Form 4 is properly executed and signed, identifies the reporting person and relationship to the issuer, and includes an explanatory note about weighted-average pricing across multiple trades. It does not indicate a Rule 10b5-1 plan or other arrangement. As filed, the document is a routine Section 16 disclosure of an insider sale and does not show any corrective amendments or unusual transfer mechanisms.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kooij Louise Frederika

(Last) (First) (Middle)

C/O NEWAMSTERDAM PHARMA COMPANY N.V.

GOOIMEER 2-35

(Street)

NAARDEN P7 1411 DC

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
NewAmsterdam Pharma Co N.V. [ NAMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/25/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	08/25/2025		S		8,269	D	$24.86(1)	15,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.74 per share to $24.92 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each transaction.

	/s/ Louise Kooij	08/27/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the NewAmsterdam Pharma insider (NAMSW) report?

The reporting person, Louise Kooij, reported a sale of 8,269 ordinary shares on 08/25/2025 at a weighted average price of $24.86 per share.

What is Louise Kooij's role at NewAmsterdam Pharma (NAMSW)?

The Form 4 lists Louise Kooij as a Director and the company's Chief Accounting Officer.

How many shares does the reporting person own after the transaction?

Following the reported sale, the filing shows the reporting person beneficially owns 15,000 ordinary shares (direct ownership).

Was the reported sale made at a single price?

No. The filing notes the reported price is a weighted average across multiple transactions with prices ranging from $24.74 to $24.92.

Does the Form 4 indicate a 10b5-1 trading plan or amendment?

The Form 4 does not indicate that the transaction was made pursuant to a Rule 10b5-1 plan, and no amendment date is provided on the form.